中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

不确定期慢性HBV感染者应个体化治疗

蒋莹莹 任姗 陈新月 郑素军

蒋莹莹,任姗,陈新月, 等. 不确定期慢性HBV感染者应个体化治疗[J]. 临床肝胆病杂志, 2021, 37(11): 2543-2544. DOI: 10.3969/j.issn.1001-5256.2021.11.009
引用本文: 蒋莹莹,任姗,陈新月, 等. 不确定期慢性HBV感染者应个体化治疗[J]. 临床肝胆病杂志, 2021, 37(11): 2543-2544. DOI: 10.3969/j.issn.1001-5256.2021.11.009
JIANG YY, REN S, CHEN XY, et al. Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated [J]. J Clin Hepatol, 2021, 37(11): 2543-2544. DOI: 10.3969/j.issn.1001-5256.2021.11.009
Citation: JIANG YY, REN S, CHEN XY, et al. Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated [J]. J Clin Hepatol, 2021, 37(11): 2543-2544. DOI: 10.3969/j.issn.1001-5256.2021.11.009

不确定期慢性HBV感染者应个体化治疗

DOI: 10.3969/j.issn.1001-5256.2021.11.009
基金项目: 

国家科技重大专项“艾滋病和病毒性肝炎等重大传染病防治” 2017ZX10302201-004

国家科技重大专项“艾滋病和病毒性肝炎等重大传染病防治” 2017ZX10202203-006

北京市医院管理中心重点医学专业发展计划(扬帆计划)资助 ZYLX202125

首都卫生发展科研专项项目 2020-1-2181

详细信息
    通讯作者:

    陈新月,chenxydoc@163.com

    郑素军,zhengsujun003@126.com

  • 中图分类号: R512.62

Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated

Research funding: 

National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Preventon and Treatment" 2017ZX10302201-004

National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Preventon and Treatment" 2017ZX10202203-006

Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support ZYLX202125

Capital Health Research and Development Projects 2020-1-2181

  • [1] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
    [2] Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [3] HUANG DQ, LI X, LE MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh.2021.01.019.[Onlineaheadofprint]
    [4] ZHANG JQ, LI MM, QI XS, et al. An excerpt of update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. J Clin Hepatol, 2018, 34(12): 2563-2567. DOI: 10.3969/j.issn.1001-5256.2018.12.011.

    张晶巧, 李苗苗, 祁兴顺, 等. 《2018年美国肝病学会乙型肝炎指引声明意见: 慢性乙型肝炎的预防、诊断和治疗》摘译[J]. 临床肝胆病杂志, 2018, 34(12): 2563-2567. DOI: 10.3969/j.issn.1001-5256.2018.12.011.
    [5] YU YC, HOU JL. The highlights of EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Clin Hepatol, 2017, 33(6): 1017-1032. DOI: 10.3969/j.issn.1001-5256.2017.06.002.

    于乐成, 侯金林. 2017年欧洲肝病学会临床实践指南: HBV感染的管理(精粹)[J]. 临床肝胆病杂志, 2017, 33(6): 1017-1032. DOI: 10.3969/j.issn.1001-5256.2017.06.002.
    [6] SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
    [7] YAO K, LIU J, WANG J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2021, 28(7): 1025-1033. DOI: 10.1111/jvh.13511.
    [8] HSU YN, PAN CQ, ABBASI A, et al. Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans[J]. Dig Dis Sci, 2014, 59(4): 865-871. DOI: 10.1007/s10620-014-3054-1.
    [9] CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50(2): 215-226. DOI: 10.1111/apt.15311.
    [10] BONACCI M, LENS S, MARIÑO Z, et al. Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone[J]. Aliment Pharmacol Ther, 2018, 47(10): 1397-1408. DOI: 10.1111/apt.14613.
  • 加载中
计量
  • 文章访问数:  74
  • HTML全文浏览量:  9
  • PDF下载量:  48
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-09-16
  • 录用日期:  2021-09-16
  • 出版日期:  2021-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回